The British Pharmaceutical Firm AstraZeneca submitted an application to conduct its Phase 3 clinical trial in the Philippines.
According to Department of Health (DOH) Undersecretary Maria Rosario Vergeire, the evaluation of the application by the vaccine experts panel and ethics board will start after the company completes its requirements.
Meanwhile, the Gamaleya vaccine, Sputnik V, has achieved a 95% efficacy rate in its 42nd day after the first dose. It was shown in the result of the 2nd interim analysis of the Phase 3 clinical trial with 40,000 volunteers. – Report from Mark Fetalco
